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ABSTRACT
Tumor cell metabolic heterogeneity is thought to contribute to tumor recurrence, 
distant metastasis and chemo-resistance in cancer patients, driving poor clinical 
outcome. To better understand tumor metabolic heterogeneity, here we used the 
MCF7 breast cancer line as a model system to metabolically fractionate a cancer 
cell population. First, MCF7 cells were stably transfected with an hTERT-promoter 
construct driving GFP expression, as a surrogate marker of telomerase transcriptional 
activity. To enrich for immortal stem-like cancer cells, MCF7 cells expressing the 
highest levels of GFP (top 5%) were then isolated by FACS analysis. Notably, hTERT-
GFP(+) MCF7 cells were significantly more efficient at forming mammospheres (i.e., 
stem cell activity) and showed increased mitochondrial mass and mitochondrial 
functional activity, all relative to hTERT-GFP(-) cells. Unbiased proteomics analysis 
of hTERT-GFP(+) MCF7 cells directly demonstrated the over-expression of 33 key 
mitochondrial proteins, 17 glycolytic enzymes, 34 ribosome-related proteins and 17 
EMT markers, consistent with an anabolic cancer stem-like phenotype. Interestingly, 
MT-CO2 (cytochrome c oxidase subunit 2; Complex IV) expression was increased by 
>20-fold. As MT-CO2 is encoded by mt-DNA, this finding is indicative of increased 
mitochondrial biogenesis in hTERT-GFP(+) MCF7 cells. Importantly, most of these 
candidate biomarkers were transcriptionally over-expressed in human breast cancer 
epithelial cells in vivo. Similar results were obtained using cell size (forward/side 
scatter) to fractionate MCF7 cells. Larger stem-like cells also showed increased hTERT-
GFP levels, as well as increased mitochondrial mass and function. Thus, this simple 
and rapid approach for the enrichment of immortal anabolic stem-like cancer cells 
will allow us and others to develop new prognostic biomarkers and novel anti-cancer 
therapies, by specifically and selectively targeting this metabolic sub-population 
of aggressive cancer cells. Based on our proteomics and functional analysis, FDA-
approved inhibitors of protein synthesis and/or mitochondrial biogenesis, may 
represent novel treatment options for targeting these anabolic stem-like cancer cells. 
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INTRODUCTION
Telomerase plays a central role both in the biology 
of normal aging, as well as in the development of human 
cancers [1, 2]. However, its exact role still remains poorly 
understood. Telomerase is a ribo-nucleoprotein, which 
contains both telomerase RNA (TERC) and telomerase 
reverse transcriptase (TERT) subunits [3]. Importantly, the 
over-expression of telomerase in both normal stem cells 
and cancer cells is sufficient to confer cell immortalization, 
such that these cells can divide beyond 50-70 divisions 
and bypass senescence [4-6]. 
Recently, Clarke and colleagues have taken 
advantage of the properties of human telomerase (hTERT), 
to enrich for a population of osteosarcoma cells with stem-
like properties [7]. For this purpose, they fused a 1.5-kB 
fragment of the hTERT promoter to GFP, in order to 
select a sub-population of osteosarcoma cells with high-
telomerase transcriptional activity by FACS analysis. 
More specifically, they demonstrated that these hTERT-
high-activity osteosarcoma cells showed increased stem-
like activity, anchorage-independent growth, invasiveness 
and metastatic activity, as well as chemo-therapy 
resistance [7]. As such, this hTERT-based approach for the 
purification of cancer stem-like cells (CSCs) has already 
been functionally validated. 
Here, we have adapted this approach to the study of 
breast cancer stem-like cells, with a focus on proteomics 
analysis, biomarker discovery and cell metabolism. 
Importantly, we demonstrate that hTERT-high-activity 
breast cancer cells form mammospheres with higher 
efficiency, and show a proteomics profile consistent 
with an anabolic cancer stem cell phenotype. In support 
of this notion, we also show that hTERT-high-activity 
breast cancer cells have increased mitochondrial mass 
and activity, consistent with an increase in mitochondrial 
biogenesis. 
RESULTS
Experimental approach: fluorescent enrichment 
of breast cancer stem cell activity
To enrich for a population of immortal CSCs, 
we exploited a sensitive eGFP reporter system for the 
fluorescent detection of high telomerase transcriptional 
activity. Briefly, MCF7 cells were transduced with a 
lentiviral vector driving eGFP protein expression, under 
the control of a 1.5-kB fragment of the hTERT promoter. 
This DNA construct also contains a puromycin-resistance 
cassette for antibiotic-resistance selection. Schematic 
diagrams illustrating this overall experimental strategy and 
the construction of the hTERT-promoter-vector are shown 
in Figures 1 and 2. 
After selection with puromycin, MCF7-hTERT-
eGFP cells were subjected to FACS analysis to visualize 
the broad distribution of eGFP expression, which serves 
as a surrogate marker of telomerase activity. Importantly, 
fewer than 1 in a 100 cells in MCF7-hTERT-eGFP cell 
monolayers visually showed high GFP fluorescence. 
In striking contrast, there was a dramatic enrichment of 
GFP(+) cells in MCF7 cell mammospheres (> 50 µm), 
each containing usually 1-to-2 GFP-high cells (Figure 2). 
To validate the enrichment of mammosphere 
forming cells, MCF7-hTERT-eGFP cells were fractionated 
into GFP-high (top 5%) and GFP-low (negative) groups. 
Then, five thousands cells from each group were seeded 
per well in 6-well low-attachment plates. These two 
groups were compared to the total unfractionated cell 
population. 
Remarkably, Figure 3 shows that GFP-high 
cells form mammospheres with an efficiency nearly 
2.5-fold greater than GFP-negative cells and the total 
unfractionated cell population. Importantly, in this 
context, mammosphere formation was sensitive to 
the administration of a well-characterized telomerase 
inhibitor, namely MST-312, as expected (Figure 3). 
Figure 1: Summary of the overall experimental 
approach, using FACS analysis, to enrich for breast 
cancer stem-like cells: Focus on telomerase and cell 
size. A. Telomerase Activity: To enrich for a population of 
immortal CSCs, we exploited a sensitive reporter system for 
the fluorescent detection of high telomerase transcriptional 
activity (hTERT-eGFP). We used this simplified approach to 
drive biomarker discovery, via unbiased label-free proteomics 
analysis. B. Cell Size (Forward Scatter/Side Scatter): 
Alternatively, we fractionated MCF7 cells based on forward/side 
scatter into larger and smaller cell populations. Previous studies 
using mouse mammary epithelial cells have demonstrated that 
stem-like cells can be enriched solely based on cell size [11]. For 
example, large stem-like cells with diameters >10 µm, defined 
by higher forward scatter during FACS analysis, showed a >4-
fold increased ability to undergo mammosphere formation. 
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Proteomics analysis of MCF7-hTERT-eGFP cells
In order to dissect the mechanism(s) by which 
high telomerase activity drives the survival and clonal 
expansion of CSCs, we next employed an unbiased label-
free proteomics approach. The proteome of fractionated 
MCF7-hTERT-eGFP cells was directly determined, after 
FACS separation into GFP-high and GFP-low populations. 
For simplicity, we focused on the proteins that were over-
expressed in GFP-high cells by > 1.5-fold. Our results are 
summarized in Tables 1, 2 and 3.
Importantly, >30 mitochondrial-related proteins 
were over-expressed in GFP-high cells (Table 1). Most of 
these proteins were related to oxidative phosphorylation, 
the TCA cycle, or mitochondrial biogenesis. Remarkably, 
MT-CO2 (a mt-DNA encoded protein) was upregulated by 
>20-fold, reflecting a significant increase in mitochondrial 
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Figure 2: Generation of MCF7 cells harboring the hTERT-eGFP reporter, to select a sub-population of cells with 
high telomerase activity. Panel A. MCF7 cells were transduced with a lentiviral vector driving eGFP protein expression, under the 
control of a 1.5-kB fragment of the hTERT promoter. This DNA construct also contains a puromycin-resistance cassette for antibiotic-
resistance selection. Panel B. After selection with puromycin, MCF7-hTERT-eGFP cells were subjected to FACS sorting to visualize the 
broad distribution of eGFP expression, which serves as a surrogate marker of telomerase activity. Panel C. Note that very few cells in 
MCF7-hTERT-eGFP monolayers showed high GFP fluorescence. Panel D. Note the dramatic enrichment of GFP(+) cells in MCF7 cell 
mammospheres (> 50 µm), each containing usually 1-to-2 GFP-high cells. 
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biogenesis. Consistent with an overall anabolic phenotype, 
17 enzymes related to glycolysis and the pentose 
phosphate pathway were also upregulated in GFP-high 
cells (Table 1). 
CSCs undergo an EMT, which facilitates cell 
migration, invasion and metastatic dissemination [8]. 
Thus, we also examined the expression of EMT markers, 
and cytoskeletal proteins associated with cell migration 
(Table 2). Greater than 17 proteins known to be associated 
with this EMT phenotype were upregulated in GFP-high 
cells. Such examples include myotrophin (>40-fold), 
keratin-19 (>15-fold), smooth muscle actin (>5-fold), and 
CD44 (>3-fold). Markers of proliferation (PCNA; >6-
fold), and the anti-oxidant response (NQO1; >6-fold) were 
also significantly increased. 
Elevated protein synthesis is another important 
feature of the anabolic CSC phenotype [9]. As predicted, 
GFP-high cells show the upregulation of >30 proteins 
related to protein synthesis (Table 3), including protein 
folding chaperones, ribosome-related proteins, translation 
initiation factors, peptide elongation factors, as well as 
enzymes for tRNA synthesis. 
Taken together, hTERT-eGFP-high cells over-
express >100 proteins related to an anabolic CSC 
phenotype. 
Relevance of hTERT targets in human breast 
cancers cells in vivo
To determine the clinical relevance of our findings, 
we next assessed whether the hTERT proteomic targets 
that we identified in GFP-high cells were transcriptionally 
over-expressed, in human breast cancer cells in vivo. For 
this purpose, we exploited a clinical data set of tumor 
samples from N = 28 breast cancer patients. These tumor 
samples were subjected to laser-capture micro-dissection, 
to separate epithelial cancer cells from adjacent tumor 
stroma [10]. Overall, greater than seventy hTERT targets 
(related to mitochondria, glycolysis, the EMT, and protein 
synthesis) that we identified in GFP-high cells were also 
transcriptionally elevated in human breast cancer cells 
in vivo. Tables 4, 5 and 6 present a detailed summary of 
these findings. These new hTERT protein targets that we 
identified in MCF7-hTERT-eGFP cells may be especially 
relevant for improving human breast cancer diagnosis and 
therapy. 
Figure 3: hTERT-eGFP-high MCF7 cells form 
mammospheres more efficiently, in a telomerase-
dependent manner. MCF7-hTERT-eGFP cells were 
fractionated into GFP-high (top 5%) and GFP-low (negative) 
groups. Then, five thousands cells from each group were 
seeded per well in 6-well low-attachment plates. These two 
groups were also compared to the total unfractionated cell 
population. Note that GFP-high cells form mammospheres with 
an efficiency nearly 2.5-fold greater than GFP-negative cells 
and the total unfractionated cell population. In this context, 
mammosphere formation was sensitive to that administration of 
a well-characterized telomerase inhibitor, namely MST-312, as 
expected. MFE, mammosphere forming efficiency. 
Figure 4: hTERT-eGFP-high MCF7 cells show an increase in mitochondrial mass. Panel A. Note that as compared to GFP-
low cells (bottom 5%), GFP-high cells (top 5%) demonstrate a significant shift to the right, for mitochondrial mass (MitoTracker Deep-Red 
probe). Panel B. FACS quantification of median fluorescence intensity is presented. As such, increased mitochondrial mass (1.3-fold) may 
be a critical element of the anabolic TIC phenotype. p < 0.001.
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Figure 5: hTERT-eGFP-high MCF7 cells show an increase in mitochondrial activity. Panel A. Note that as compared to 
GFP-low cells (bottom 5%), GFP-high cells (top 5%) demonstrate a significant shift to the right, for mitochondrial membrane potential 
(MitoTracker Orange probe). Panel B: FACS quantification of median fluorescence intensity is presented, representing a 1.7-fold increase. 
p < 0.001.
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hTERT-eGFP-high MCF7 cells show an increase 
in mitochondrial mass and functional activity
To directly validate the mitochondrial phenotype 
of hTERT-eGFP-high cells (top 5%), we used two well-
established fluorescent probes to quantitate mitochondrial 
membrane potential and mass, by FACS analysis. More 
specifically, we used MitoTracker Orange (561-nm) 
as a reporter for mitochondrial membrane potential 
and MitoTracker Deep-Red (640-nm) as a marker of 
mitochondrial mass. Importantly, Figures 4 and 5 show 
that as compared to GFP-low cells (bottom 5%), GFP-high 
cells (top 5%) demonstrate a significant shift to the right, 
for both mass and membrane potential. FACS quantitation 
of median fluorescence intensity shows that both of these 
mitochondrial-related measurements are significantly 
elevated in GFP-high cells. As such, mitochondrial mass 
and function may be critical elements of the anabolic TIC 
phenotype. 
Using large cell size to enrich telomerase activity 
and mitochondrial mass
Previous studies using mouse mammary epithelial 
cells have demonstrated that stem-like cells can be 
enriched solely based on cell size [11]. For example, large 
stem-like cells with diameters >10 µm, defined by higher 
forward scatter during FACS analysis, showed a >4-fold 
increased ability to undergo 3-D mammosphere formation. 
Moreover, these large stem-like mammary cells also had 
the ability to efficiently repopulate and regenerate the 
mammary gland in vivo [11]. 
Thus, here we fractionated MCF7-hTERT-eGFP 
cells by size, based on forward/side scatter, into two 
populations: i) larger cells (~15% of the total population) 
and ii) smaller cells (~85% of the total population) (Figure 
6). Interestingly, larger MCF7 cells showed a 2.65-fold 
increase in hTERT-eGFP fluorescence, as compared 
with the smaller cell population. Importantly, larger 
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cells also showed a 1.6-fold increase in mitochondrial 
mass (MitoTracker Deep-Red) and a 2.4-fold increase in 
mitochondrial activity (membrane potential), as measured 
using MitoTracker Orange (Figure 6).
As such, larger cell size in MCF7 cells directly 
correlates with telomerase activity (cell immortalization) 
and mitochondrial mass/activity, which would be 
consistent with an anabolic CSC phenotype. These results 
provide independent validation for the idea that high 
hTERT activity (“stemness”) is functionally associated 
with increased mitochondrial mass and activity in breast 
cancer cells, and co-segregates with large cell size. 
Importantly, large cell size is determined by increased 
PI3K/AKT/mTOR-signaling, which drives significant 
increases in overall protein synthesis [12-14]. This finding 
is consistent with our results from proteomics analysis, 
showing an increase in the abundance of the protein 
synthesis machinery (See Tables 3 and 6). 
DISCUSSION
Here, we have used an hTERT-promoter-eGFP-
reporter system to identify and purify a sub-population 
of MCF7 cells, with high hTERT transcriptional activity, 
by FACS analysis. These hTERT-eGFP-high cells formed 
mammospheres with greater efficiency, as predicted, 
consistent with the idea that this sub-population of 
cells is enriched in cancer stem-like cells. Importantly, 
proteomics analysis of these hTERT-eGFP-high MCF7 
cells revealed the upregulation of mitochondrial 
proteins, glycolytic enzymes and EMT markers, as well 
as components of the protein synthesis machinery, such 
as ribosome-related proteins and chaperones for protein 
folding. Interestingly, MT-CO2 (cytochrome c oxidase 
subunit 2; Complex IV) expression was increased by >20-
fold. As MT-CO2 is encoded by mt-DNA, this finding 
is indicative of increased mitochondrial biogenesis in 
hTERT-eGFP-high MCF7 cells. We then functionally 
validated that hTERT-eGFP-high MCF7 cells show 
increases in mitochondrial mass and activity, using two 
distinct MitoTracker probes. Complementary results were 
obtained using cell size to fractionate MCF7 cells. Larger 
stem-like cells showed increased hTERT-GFP levels, as 
well as increased mitochondrial mass and function. Thus, 
these two independent approaches for the enrichment of 
immortal anabolic CSCs should allow the development of 
new prognostic biomarkers and related novel anti-cancer 
Figure 7: Understanding the role of immortality, 
anabolic metabolism and cell size in stem-like cancer 
cells. Here, we used FACS analysis to begin to dissect metabolic 
heterogeneity in tumor cells. More specifically, we showed that 
anabolic stem-like cancer cells can be purified using hTERT-
eGFP as a surrogate marker of telomerase activity. These eGFP-
high cells showed increased stem cell activity (mammosphere 
formation), as well as functional increases in mitochondrial mass 
and activity. Further studies with unbiased label-free proteomics 
revealed the upregulation of mitochondrial proteins, glycolytic 
enzymes and EMT markers, as well as ribosome subunits and 
other components of the proteins synthesis machinery. These 
proteomic studies are consistent with, and support an anabolic 
stem-like cancer cell phenotype. Quantitatively similar results 
were obtained using large cell size to purify anabolic stem-like 
cancer cells. We speculate that high telomerase activity drives 
an increase in mitochondrial power, via positive regulation by 
PGC1-α/β. Moreover, we suggest that increased mTOR signaling 
may contribute to larger cell size, via increased protein synthesis. 
The PI3K/AKT/mTOR pathway is known to i) control cell size 
by positively regulating protein synthesis and ii) telomerase 
(hTERT) forms a physical complex with mTOR and can therefore 
regulate its activity. In summary, our results metabolically define 
a sub-population of stem-like, mitochondrial-rich, cancer cells, 
allowing us to understand the possible origins of metabolic 
heterogeneity in human tumors. 
Figure 6: Fractionation of hTERT-eGFP MCF7 
cells by cell size allows the separation of larger and 
smaller cell sub-populations, with distinct metabolic 
functional properties. We fractionated MCF7-hTERT-eGFP 
cells based on forward/side scatter into larger and smaller cell 
populations. Note that larger MCF7 cells showed a 2.65-fold 
increase in hTERT-eGFP fluorescence, as compared with the 
smaller cell population. Similarly, larger cells also showed a 1.6-
fold increase in mitochondrial mass (MitoTracker Deep-Red) 
and a 2.4-fold increase in mitochondrial activity (membrane 
potential), as measured using MitoTracker Orange. Thus, 
larger cell size directly correlates with telomerase activity and 
mitochondrial mass/activity, which would be consistent with an 
anabolic CSC phenotype. 
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therapies.
Interestingly, recent studies in aging and cancer have 
both directly linked telomerase activity to mitochondrial 
function, via the hTERT-p53-PGC1 signaling axis 
[15-18]. More specifically, telomerase is required for 
the proper expression of PGC1-α/β, a major nuclear-
encoded mitochondrial transcription factor. Studies in 
aging demonstrate that a loss of telomerase functionally 
impairs mitochondria, via the induction of p53 which 
down-regulates PGC1-α/β expression [16]. Conversely, 
during tumorigenesis, high telomerase expression 
helps to promote cancer progression, by reducing p53 
and, therefore, elevating PGC1-α/β expression [19-
21]. Taken together, these mechanistic studies are 
consistent with our current findings, in which we link 
telomerase transcriptional activity in cancer stem cells 
to mitochondrial biogenesis, both functionally and via 
proteomics analysis (Figure 7). 
Cell size is normally controlled by the PI3K/AKT/
mTOR-pathway, which converges on protein synthesis, 
via S6-kinase signaling [12]. Therefore, large cell size is 
known to be associated with increased protein synthesis 
[13, 14]. Interestingly, telomerase (hTERT) forms a 
physical complex with mTOR and can therefore regulate 
its functional activity [22, 23]. Consistent with this 
hypothesis, we demonstrate here that stem-like anabolic 
cancer cells, with high-telomerase transcriptional activity, 
also show remarkable increases in i) protein synthesis 
machinery (chaperones, ribosome-related proteins, 
translation initiation factors, peptide elongation factors, 
enzymes for tRNA synthesis) and ii) are associated with 
large cell size (Figure 7).
Interestingly, large cell size is also a conserved 
characteristic of circulating tumor cells (CTCs), which 
share several properties with CSCs or TICs [24-26]. For 
example, CTCs – like CSCs – are found in clusters, are 
associated with distant metastasis, and can initiate tumor 
formation in xenografted mice [27]. Also, recent studies 
demonstrate that CTCs show an increase in mitochondrial 
mass and OXPHOS, most likely reflecting increased 
mitochondrial biogenesis, secondary to elevated levels of 
PGC1-α/β [28].
We recently directly compared the proteome of 
MCF7 cell monolayers to MCF7-derived mammospheres, 
using label-free unbiased proteomics analysis. Consistent 
with our current findings, this analysis demonstrated 
that MCF7-derived mammospheres show the over-
expression of >60 mitochondrial-related proteins and >80 
components of the protein synthesis machinery [9, 29]. 
Complementary results were also obtained with MCF7 
cells transfected with FOXM1, a key stem cell associated 
transcription factor that is a downstream target of the Wnt/
β-catenin signaling pathway [30]. Interestingly, MCF7-
FOXM1 cells showed a >3-fold increase in mammosphere 
formation, as compared with empty-vector alone control 
cells. Thus, several independent proteomic data sets now 
show the conserved up-regulation of both i) mitochondrial 
biogenesis and ii) protein synthesis, as key elements of the 
anabolic CSC phenotype. 
Importantly, functional validation studies revealed 
that mammosphere formation could be efficiently blocked 
with well-established inhibitors of mitochondrial function 
and/or inhibitors of protein synthesis, such as oligomycin 
A and puromycin, respectively [9, 29]. Moreover, FDA-
approved drugs which inhibit mitochondrial biogenesis 
or OXPHOS as a manageable side-effect (azithromycin, 
doxycycline and pyrvinium pamoate) also efficiently 
blocked mammosphere formation [31]; an FDA-approved 
inhibitor of protein synthesis, namely rapamycin, inhibited 
mammosphere formation as well [9]. Remarkably, the 
growth of mammosphere cultures derived from primary 
breast cancer cells (isolated from metastatic disease sites) 
was sensitive to inhibition with doxycycline [32]. Thus, 
these diverse classes of FDA-approved drugs should all 
be considered for testing in future phase II clinical trials, 
such as window-of-opportunity trials. In direct support 
of this idea, everolimus (Afinitor; a rapamycin-analogue 
and inhibitor of protein synthesis) has already shown 
significant efficacy in clinical trials in breast cancer 
patients [33]. 
In summary, we show here that high telomerase 
activity metabolically defines a sub-population of anabolic 
CSCs, with increased mitochondrial mass and large 
cell size. Overall, greater than seventy hTERT targets 
(related to mitochondria, glycolysis, the EMT, and protein 
synthesis) that we identified in hTERT-eGFP-high cells 
were also transcriptionally elevated in human breast cancer 
cells in vivo. Thus, the new hTERT metabolic targets that 
we identified here may be important for improving human 
breast cancer diagnosis and therapy. 
MATERIALS AND METHODS
Materials
MCF7 cells were purchased from the ATCC. Gibco-
brand cell culture media (DMEM and DMEM/F12) 
was purchased from Life Technologies. The lentiviral 
vector encoding the hTERT promoter linked to eGFP 
was custom-made by Genecopoeia (USA). MitoTracker 
probes (Deep Red and Orange) were purchased from 
Molecular Probes/Invitrogen, via Life Technologies. 
The telomerase inhibitor IX (MST-312; sc-204333) was 
obtained commercially from Santa Cruz Biotech (USA).
Construction of the hTERT-eGFP lentiviral vector
The following 1.5 kB sequence was used as the 
hTERT-promoter to generate the hTERT-eGFP-PuroR 
cassette, and cloned into a lentiviral vector, custom-made 
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by Genecopoeia:
5’-TAAAATTGTGTTTTCTATGTTGGCTTCTCTGC 
AGAGAACCAGTGTAAGCTACAACTTAACTTTTGTTGG 
AACAAATTTTCCAAACCGCCCCTTTGCCCTAGTGCA 
GAGACAATTCACAAACACAGCCCTTTAAAAAGGCTT 
AGGGATCACTAAGGGGATTTCTAGAAGAGCGACCTG 
TAATCCTAAGTATTTACAAGACGAGGCTAACCTCCAGG 
AGCGTGACAGCCCAGGGAGGGTGCGAGGCCTG 
TTCAAATGCTAGCTCCATAAATAAAGCAATTTCCTCC 
GGCAGTTTCTGAAAGTAGGAAAGGTTACATTTAA 
GGTTGCGTTTGTTAGCATTTCAGTGTTTGCCGACCT 
CAGCTACAGCATCCCTGCAAGGCCTCGGGAGAC 
CCAGAAGTTTCTCGCCCCTTAGATCCAAACTTGAGC 
AACCCGGAGTCTGGATTCCTGGGAAGTCCTAGCTG 
TC C TG CG G T TG TG C CG G G G C C C C AG G TC TG G 
AGGGGACCAGTGGCCGTGTGGCTTCTACTGCTGGG 
C TG G A AGTCG G G C C TC C TAG C TC TG C AGTC C -
GAGGCTTGGAGCCAGGTGCCTGGACCCCGAG-
GTTGCCCTCCACCCTGTGCGGGCGGGATGTGACC 
AGATGTTGGCCTCATCTGCCAGACAGAGTGCCG 
GGGCCCAGGGTCAAGGCCGT TGTGGC TGGTG 
TGAGGCGCCCGGTGCGCGGCCAGCAGGAGCG 
CCTGGCTCCATTTCCCACCCTTTCTCGACGGGACC 
GCCCCGGTGGGTGATTAACAGATTTGGGGTGG 
T T TG C TC ATG G TG G G G A C C C C TC G C C G C C TG 
AGAACC TGCAAAGAGAAATGACGGGCC TGTG 
TCAAGGAGCCCAAGTCGCGGGGAAGTGT TGC 
AGGGAGGCACTCCGGGAGGTCCCGCGTGCCCGTCC 
AGGGAGCAATGCGTCCTCGGGTTCGTCCCCAGCCG 
CGTCTACGCGCCTCCGTCCTCCCCTTCACGTCCGGC 
ATTCGTGGTGCCCGGAGCCCGACGCCCCGCGTC-
CGGACCTGGAGGCAGCCCTGGGTCTCCGGATCAG-
GCCAGCGGCCAAAGGGTCGCCGCACGCACCTG 
TTCCCAGGGCCTCCACATCATGGCCCCTCCCTCG 
GGTTACCCCACAGCCTAGGCCGATTCGACCTCTCTCC 
GCTGGGGCCCTCGCTGGCGTCCCTGCACCCTGGG 
AGCGCGAGCGGCGCGCGGGCGGGGAAGCGCGG 
CCCAGACCCCCGGGTCCGCCCGGAGCAGCTGCG 
CTGTCGGGGCCAGGCCGGGCTCCCAGTGGATTCG 
CGGGCACAGACGCCCAGGACCGCGCTTCCCACG 
TG G CG G AG G G AC TG G G G AC C CG G G C AC C CG 
TCCTGCCCCTTCACCTTCCAGCTCCGCCTCCTCC 
G C G C G G A C C C C G C C C C G TC C C G A C C C C TC C C 
G G G T C C C C G G C C C A G C C C C C T C C G G G C C C 
TCCCAGCCCCTCCCCT TCCT T TCCGCGGCCCCG 
CCCTCTCCTCGCGGCGCGAGTT-3’.
Viral transduction and cell selection
Lentiviral particles harboring the hTERT-eGFP-
PuroR cassette were prepared and used to stably transduce 
MCF7 cells, according to the manufacturer’s protocol (in 
the presence of 5 μg/ml polybrene). Twenty-four hours 
post-infection, media containing the virus was removed 
and replaced with standard media. Cells were then 
selected with puromycin (2 μg/ml), for up to 10 days. 
Please note that for most of the experiments described in 
this paper, we compared the GFP-high (top 5%) fraction 
to the GFP-low/negative (bottom 5%) fraction, unless 
stated otherwise. However, for label-free proteomics 
analysis, we compared the GFP-high (top 10%) population 
to the GFP-low (bottom 10%) population, to insure that 
enough material was collected for sample processing. For 
these experiments, singlet FACS gating of live cells was 
utilized.
Mammosphere formation
A single cell suspension of MCF7-hTERT-eGFP 
cells was prepared using enzymatic (1x Trypsin-EDTA, 
Sigma Aldrich, #T3924), and manual disaggregation 
(25 gauge needle) [34]. Cells were then plated at a 
density of 500 cells/cm2 in mammosphere medium 
(DMEM-F12/ B27 / 20-ng/ml EGF/PenStrep) in non-
adherent conditions, in culture dishes coated with 
(2-hydroxyethylmethacrylate) (poly-HEMA, Sigma, 
#P3932). Cells were grown for 5 days and maintained 
in a humidified incubator at 37°C at an atmospheric 
pressure in 5% (v/v) carbon dioxide/air. After 5 days for 
culture, spheres >50 µm were counted using an eye piece 
graticule, and the percentage of cells plated which formed 
spheres was calculated and is referred to as percentage 
mammosphere formation, and was normalized to one (1 
= 100% MSE). Mammosphere assays were performed in 
triplicate and repeated three times independently.
Treatment with telomerase inhibitor (MST-312)
Cells were treated on day 0 with MST-312 at 
a concentration of 10 µM and compared to vehicle 
alone controls, processed in parallel, after 5 days of 
mammosphere culture. A dose-response analysis of the 
effects of MST-312 on parental MCF7 cells was first 
performed to establish an effective concentration for the 
inhibition of mammosphere formation; our results showed 
that 1 µM had little or no effect, while 10 µM inhibited 
mammosphere formation by approximately 70% (data not 
shown). Therefore, experiments with eGFP fractionated 
MCF7 cells were carried out at 10 µM. 
Microscopy
Fluorescent imaging of MCF7 cells in adherent 
conditions and non-adherent spheroid culture was 
performed using a Leica SP8 multi-photon DM6000 
microscope to detect GFP expression and bright field 
images. 
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Proteomics analysis
Cell lysates were prepared for trypsin digestion 
by sequential reduction of disulphide bonds with TCEP 
and alkylation with MMTS [35]. Then, the peptides were 
extracted and prepared for LC-MS/MS. All LC-MS/MS 
analyses were performed on an LTQ Orbitrap XL mass 
spectrometer (Thermo Scientific, San Jose, CA) coupled to 
an Ultimate 3000 RSLCnano system (Thermo Scientific, 
formerly Dionex, The Netherlands). Xcalibur raw data 
files acquired on the LTQ-Orbitrap XL were directly 
imported into Progenesis LCMS software (Waters Corp., 
Milford, MA, formerly Non-linear dynamics, Newcastle 
upon Tyne, UK) for peak detection and alignment. Data 
were analyzed using the Mascot search engine. Five 
technical replicates were analyzed for each sample type. 
Statistical analyses were performed using ANOVA and 
only fold-changes in proteins with a p-value less than 0.05 
were considered significant. 
Bioinformatics analysis with human clinical 
samples
To firmly establish the clinical relevance of our 
results from the quantitative proteomics, we re-analyzed 
the transcriptional profiles of epithelial breast cancer cells 
and adjacent tumor stromal cells that were physically 
separated by laser-capture microdissection (from N = 28 
human breast cancer patients) [10].
FACS analysis
For live cell sorting experiments, hTERT-eGFP 
transfected MCF7 cells were resuspended in PBS and 
sorted according to eGFP expression using the BD influx. 
Untransfected MCF7 cells were used as a negative control 
to determine positive GFP expression. Cells were sorted 
into two groups, those with the highest GFP expression 
and those with the lowest GFP expression. For FACs 
analysis experiments, hTERT-eGFP cells were labeled 
with MitoTracker Deep Red (#M22426, Invitrogen) and 
MitoTracker Orange ((#M7510, Invitrogen). Cells were 
kept of ice until analysis using the FACS Calibur. Results 
were analyzed using FlowJo software version 10. Cells 
were gated into two populations, those with the highest 
5% of GFP expression, and those with the lowest 5% and 
negative GFP expression. The median fluorescent intensity 
of MitoTracker Deep Red (640nm) and MitoTracker 
Orange (561nm) was then determined within the two 
distinct GFP cellular populations. Additionally, cells were 
discriminated by cell size into two populations, small and 
large using SSC (side scatter) and FSC (forward scatter). 
The median intensity of eGFP, MitoTracker Deep Red, 
and MitoTracker Orange, within these populations, was 
then determined. 
Mitochondrial staining
To measure mitochondrial activity, cells were 
stained with MitoTracker Orange (#M7510, Invitrogen), 
whose accumulation in mitochondria is dependent upon 
membrane potential. To measure mitochondrial mass, 
cells were stained with MitoTracker Deep Red (#M22426, 
Invitrogen), localizing to mitochondria regardless of 
mitochondrial membrane potential. Cells were incubated 
with pre-warmed MitoTracker staining solution (diluted 
in PBS/CM to a final concentration of 10 nM) for 30-60 
min at 37 °C. All subsequent steps were performed in 
the dark. Cells were washed in PBS, harvested, and re-
suspended in 300 μL of PBS. Cells were then analyzed 
by flow cytometry. Data analysis was performed using 
FlowJo software.
Fractionation of MCF7 by cell size
hTERT-eGFP-MCF7 cells, co-labeled with 
MitoTracker dyes, were analyzed by cell size using FlowJo 
software. Cells were separated by gating of forward scatter 
(FSC) and side scatter (SSC) plots into two populations 
for analysis, large cells (~15% of the total population) and 
small cells (~85% of the total population). The median 
fluorescent intensity of eGFP and MitoTracker dyes were 
determined in each population of cells. Very similar results 
were obtained, with either singlet FACS gating or all live 
cell FACS gating. 
Statistical analyses
Statistical significance was determined using the 
Student’s t-test or ANOVA, where appropriate. Values of 
less than 0.05 were considered significant. Data are shown 
as the mean ± SEM, unless stated otherwise. 
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